ライフサイエンスコーパス: vascular disease

1 cular disease, heart failure, and peripheral vascular disease).

2 c therapy for long-term treatment of chronic vascular disease.

3 ajor vascular events in patients with stable vascular disease.

4 icacy of antiangiogenic therapies in retinal vascular disease.

5 apeutic modulation could benefit age-related vascular disease.

6 role that B lymphocytes play in cardiac and vascular disease.

7 g patients with pre-existing atherosclerotic vascular disease.

8 als and dictate management of the associated vascular disease.

9 blood vessels in cancer and atherosclerotic vascular disease.

10 tients with SAPH and pre-capillary pulmonary vascular disease.

11 linical threshold, had a higher frequency of vascular disease.

12 reatment of pulmonary hypertension and other vascular disease.

13 ted a mechanistic role for CHIP in promoting vascular disease.

14 impaired HDL function or RCT contributes to vascular disease.

15 or an anti-inflammatory approach in diabetic vascular disease.

16 ntribute to different VSMC behavior and thus vascular disease.

17 ism (PE) is a serious and prevalent cause of vascular disease.

18 ease but lower odds of small-vessel cerebral vascular disease.

19 l cells, this phenomenon might contribute to vascular disease.

20 elopment of TAAD and proliferative occlusive vascular disease.

21 erating room for young children with retinal vascular disease.

22 rtant atheroprotective potential in diabetic vascular disease.

23 ment of diabetic bone marrow mobilopathy and vascular disease.

24 mal amino acid metabolism is associated with vascular disease.

25 gest that TSPAN2 may play important roles in vascular disease.

26 fibrous cap stability with implications for vascular disease.

27 asive hemodynamics consistent with pulmonary vascular disease.

28 ation, progression and clinical treatment of vascular disease.

29 variety of inflammatory conditions including vascular disease.

30 macrophages as a therapy for atherosclerotic vascular disease.

31 novel therapeutic target for atherosclerotic vascular disease.

32 ource OCTA (MIOCTA) in children with retinal vascular disease.

33 fferentiation and negatively correlated with vascular disease.

34 ary stress failure, and eventually pulmonary vascular disease.

35 ve the potential to mediate cytotoxicity and vascular disease.

36 ular pathological changes and development of vascular disease.

37 nd 29.8 (21.7-40.8) for diabetes followed by vascular disease.

38 es, types, and consequences of DNA damage in vascular disease.

39 hronic pulmonary insufficiency; and cerebral vascular disease.

40 ricular stiffness, and concomitant pulmonary vascular disease.

41 y CCN3 as a potential therapeutic target for vascular disease.

42 ce of this bacterium in the circulation with vascular disease.

43 issues and for preventing the development of vascular disease.

44 gration, which are processes associated with vascular disease.

45 utic strategy to improve diabetes-associated vascular disease.

46 te diabetes-induced comorbidities related to vascular disease.

47 rombosis pathways lead to SARS-CoV-2-induced vascular disease.

48 ies become mainstays of surgical therapy for vascular disease.

49 ominal aortic aneurysm (AAA), an age-related vascular disease.

50 right heart failure, and worsening pulmonary vascular disease.

51 lar inflammation and thus the progression of vascular disease.

52 osis to better understand the role of AHR in vascular disease.

53 gration, which are processes associated with vascular disease.

54 al of interfering with this pathway to treat vascular disease.

55 reased bleeding risk in patients with stable vascular disease.

56 ctive management of patients with peripheral vascular disease.

57 dent neuronal phase of disease that precedes vascular disease.

58 PLN analogs provide an effective therapy for vascular diseases.

59 apy specific to pediatric lung and pulmonary vascular diseases.

60 orm the arterial wall contribute to multiple vascular diseases.

61 rtension, stroke, myocardial infarction, and vascular diseases.

62 ammation in a target organ (eg, the skin) on vascular diseases.

63 r factor contributing to the pathogenesis of vascular diseases.

64 umab, rescue vision in patients with retinal vascular diseases.

65 y role in the pathogenesis of a multitude of vascular diseases.

66 d contribute to the pathogenesis of multiple vascular diseases.

67 e acutely lethal manifestations of heart and vascular diseases.

68 in microvascular dysfunction in CAD or other vascular diseases.

69 red blood cells has been implicated in many vascular diseases.

70 rt disease, stroke, heart failure, and other vascular diseases.

71 ew therapeutic compounds to treat PD-induced vascular diseases.

72 sms, acute aortic dissections, and occlusive vascular diseases.

73 a therapeutic approach in TGF-beta-dependent vascular diseases.

74 ificant implications for the pathogenesis of vascular diseases.

75 g therapeutic strategy for treatment of many vascular diseases.

76 to TNFalpha-induced inflammation in retinal vascular diseases.

77 ple, in a number of allergic, cutaneous, and vascular diseases.

78 d is believed to initiate the development of vascular diseases.

79 tory and affective disorders associated with vascular diseases.

80 e targeted to modulate VSMC phenotype during vascular diseases.

81 recommendation for the prevention of cardio-vascular diseases.

82 ereby preventing the development of ischemic vascular diseases.

83 ctive platform enabling treatment of chronic vascular diseases.

84 tion in the normal eye as well as in retinal vascular diseases.

85 nd improve outcomes in patients with retinal vascular diseases.

86 phenotypic modulation in the pathogenesis of vascular diseases.

87 that can successfully treat a wide range of vascular diseases.

88 rose: heart failure (13.9%-34.4%), pulmonary vascular disease (1.2%-7.1%), valvular heart disease (5.

89 disease (38%), diabetes (26%) and peripheral vascular disease (14.5%).

90 on (40.7% versus 47.9%; P<0.001), peripheral vascular disease (2.4% versus 3.3%; P=0.002), tobacco us

91 ons (12.8%), bleeding (7.6%), and peripheral vascular disease (4.3%) were the most common noncardiac

92 revious stroke or transient ischemic attack, vascular disease, 65 to 74 years of age, female) score w

93 and its transition with risks of subtypes of vascular disease across body mass index (BMI) categories

94 leeper were higher among men with peripheral vascular disease (adjusted odds ratio (aOR) = 6.54, 95%

95 cs have led to a deeper understanding of how vascular disease affects cognition.

96 Peripheral vascular disease affects millions of individuals worldwi

97 Diabetes, Stroke/transient ischemic attack, Vascular disease, Age 65 to 74 years, Sex category) >=2,

98 mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) scor

99 abetes mellitus, prior stroke/TIA (doubled), vascular disease, age 65-74 years, sex category (female)

100 years [doubled], diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category [female]

101 Age >= 75 years, Diabetes, previous Stroke, Vascular disease, Age 65-74 years, Sex category) score >

102 re (HF), atrial fibrillation, and peripheral vascular disease, all of which were associated with all-

103 Interestingly, systemic vascular diseases also occur in glaucoma patients and ar

104 ous thromboembolism (VTE), which is a common vascular disease and a major cause of morbidity and mort

105 jects; (ii) the association between systemic vascular disease and cerebral small vessel disease is st

106 the influence of disease status on systemic vascular disease and cerebral small vessel disease score

107 uable insights into patients' risk of future vascular disease and death.

108 Aging is the main risk factor for vascular disease and ensuing cardiovascular and cerebrov

109 Vascular disease and heart failure impart an enormous bu

110 Peripheral vascular disease and IADL impairment, but not chronologi

111 f e-cigarettes versus combustible tobacco in vascular disease and implications for blood-brain barrie

112 nt of the diagnosis of cardiac and pulmonary vascular disease and interventions aimed at managing the

113 a role in the pathogenesis of hypertension, vascular disease and kidney damage in humans and animals

114 F were more congested with greater pulmonary vascular disease and lower cardiac output.

115 atherosclerosis, the most prevalent chronic vascular disease and root cause of myocardial infarction

116 subgroups stratified by markers of pulmonary vascular disease and RV dysfunction.

117 Atherosclerosis is a chronic inflammatory vascular disease and the predominant cause of heart atta

118 highlights the important role of the ECM in vascular disease and the prospect of translating these d

119 c of 6.5% to 10.0%, high CV risk (history of vascular disease and urine-albumin creatinine ratio [UAC

120 r patients with DME who are at high risk for vascular disease and were not included in these trials.

121 ty and by interrogating their association to vascular diseases and cancer co-expression patterns repo

122 enues for the study and treatment of retinal vascular diseases and choroid-related inflammatory blind

123 several diseases including cancer, ischemic vascular disease, and Alzheimer's disease.

124 abetes in overweight and obese patients with vascular disease, and pay increased attention to prevent

125 ic studies regarding n-3 FAs, vitamin D, and vascular disease, and summarize recent meta-analyses of

126 pathways in angiogenesis relevant to cancer, vascular diseases, and wound healing.

127 ic rhinitis, mitral valve prolapse, collagen vascular disease, aortic aneurysm, Down syndrome, sleep

128 PM exposure and associated vascular disease are a global health burden.

129 H), endothelial dysfunction and obliterative vascular disease are associated with DNA damage and impa

130 Both forms of vascular disease are driven by diverse risk factors, wit

131 Collateral pathways in vascular disease are important natural "bypass" conduits

132 r physiological importance in the setting of vascular disease are unclear.

133 Retinal vascular diseases are among the leading causes of acquir

134 lar inflammation and associated inflammatory vascular diseases are not well defined.

135 Cocoa flavanols protect humans against vascular disease, as evidenced by improvements in periph

136 ts with diabetes mellitus and no evidence of vascular disease, aspirin significantly reduced serious

137 y have therapeutic value in the treatment of vascular disease associated with diabetes.

138 secretion as a potential target for treating vascular disease-associated skeletal muscle dysfunction.

139 ranslates to a lower risk of atherosclerotic vascular disease (ASVD) mortality.The objective was to i

140 ns of LDL-C >/=190 mg/dL without preexisting vascular disease at baseline.

141 after excluding individuals with evidence of vascular disease at baseline.

142 ry setting, including medical strategies for vascular disease, atrial fibrillation, and heart failure

143 w in Fontan circulation results in pulmonary vascular disease, but the potential relationships betwee

144 rall, our studies illuminate how a prominent vascular disease can be distantly driven by a cytokine-d

145 ological conditions, including inflammation, vascular diseases, cancer mortality, and high risk for h

146 ation-related pathological states, including vascular diseases, cancer, neurodegeneration and diabete

147 intervals (CIs) for risk of cardio-cerebral-vascular disease (CCVD) associated with COex levels, wit

148 diabetes mellitus, heart failure, peripheral vascular disease, chronic kidney disease, chronic obstru

149 , previous stroke/transient ischemic attack, vascular diseases, chronic kidney disease and chronic ob

150 Numerous vascular risk factors and vascular diseases contribute to cognitive impairment and

151 Diabetes increases the risk of Cardio-vascular disease (CVD).

152 enous pressure (CVP) abnormalities in cardio-vascular diseases (CVDs) diagnosis.

153 Minimally invasive treatment of vascular disease demands dynamic navigation through comp

154 PP, and beta-amyloid (Abeta) are linked with vascular disease development and increased BACE1 and Abe

155 , age, smoking, antiplatelet drugs, previous vascular disease, diabetes mellitus, blood pressure, est

156 ystolic and diastolic dysfunction, pulmonary vascular disease, endothelial dysfunction, and periphera

157 d, cancer itself serves as a risk factor for vascular disease, especially by increasing the risk for

158 Peripheral vascular disease existed in 308 KT candidates at waitlis

159 eart disease or stroke), 12.0 (8.1-17.9) for vascular disease followed by diabetes, 18.6 (16.6-20.9)

160 Of 47 611 patients with stable vascular disease followed for 3 years in both studies th

161 nd cancer survivors are at increased risk of vascular disease for a number of reasons.

162 436 patients with various manifestations of vascular disease from the TNT (Treating to New Targets),

163 In patients with vascular disease, further risk stratification can identi

164 sing computerized tomography, PLWHIV without vascular disease had higher rates of any carotid plaque

165 ; 95% CI, 1.15 to 6.36), whereas preexisting vascular disease had no association with HF ( P > .05).

166 predictor of kidney disease progression and vascular disease has driven research in this area.

167 arcts (CMIs), a novel MRI marker of cerebral vascular disease, have not been studied, to date, in rel

168 For DDKT recipients, peripheral vascular disease (hazard ratio [HR] 3.04, 95% confidence

169 iovascular Events [e.g., Death From Heart or Vascular Disease, Heart Attack, or Stroke] in Patients W

170 n inflammation (eg, in the skin) may improve vascular diseases; however, randomized clinical trials a

171 sk of a hospitalization for other peripheral vascular disease (HR: 0.53; 95% CI: 0.42, 0.67).

172 his is mediated by an excess of extracranial vascular disease (i.e. atherosclerosis) and/or of cerebr

173 W83-derived OMVs induced significantly more vascular disease in a zebrafish larvae systemic infectio

174 response to complement injury and choroidal vascular disease in age-related macular degeneration.

175 and pay increased attention to prevention of vascular disease in obese individuals with diabetes.

176 to ASA monotherapy in patients with chronic vascular disease in the COMPASS study cohort (intention-

177 These findings are consistent with a role of vascular disease in the development of Alzheimer disease

178 n applied in combination to evaluate retinal vascular disease in the operating suite.

179 osis and management of cardiac and pulmonary vascular disease in this population are provided to offe

180 involved in the pathogenesis of subclinical vascular disease in this population.

181 involved in the pathogenesis of subclinical vascular disease in this population.

182 ngs implicate plasma PK as a risk factor for vascular disease in type 1 diabetes.

183 s is a means to causally control early-stage vascular disease in type I diabetic mice.

184 Aortic aneurysms are a common vascular disease in Western populations that can involve

185 r complications of diabetes has been useful, vascular diseases in diabetes may be more interrelated t

186 rged as a significant contributor to retinal-vascular diseases in the previous 2 decades.

187 eir functions as mediators or antagonists of vascular diseases in vivo.

188 inflammation, there is a wide range of other vascular diseases in which macrophages and inflammation

189 he interstitium, which characterizes several vascular diseases including acute lung injury.

190 mplications of neuromuscular conditions, and vascular disease, including aortopathies.

191 in regulating angiogenesis in health and in vascular disease, including VEGF-A(121) and an anti-angi

192 te the PHACTR1 locus (6p24) in risk for five vascular diseases, including coronary artery disease, mi

193 TR1/EDN1 is a genetic risk locus for several vascular diseases, including FMD and coronary artery dis

194 revolutionized the treatment of intraocular vascular diseases involving the retina and choroid.

195 This suggests that pulmonary vascular disease is a key mechanism underlying Fontan fa

196 Peripheral vascular disease is a strong predictor of mortality in K

197 Vascular disease is associated with marked changes in th

198 Early detection of vascular disease is crucial to preventing cardiovascular

199 -cigarette aerosol, and their involvement in vascular disease is discussed.

200 standing of the pathophysiology of pulmonary vascular disease is incomplete, since information about

201 Atherothrombotic vascular disease is often triggered by a distinct type o

202 DCB) therapy for the treatment of peripheral vascular disease is that it allows for reopening of the

203 this also holds for a spectrum of peripheral vascular diseases is unknown.

204 ement of Rho proteins in the pathogenesis of vascular diseases is well studied, little is known about

205 ulmonary hypertension (PH), a hypoxia-driven vascular disease, is characterized by a glycolytic switc

206 soconstrictive and inflammatory signaling in vascular disease, is overexpressed aberrantly in some br

207 eview of studies published in top peripheral vascular disease journals to determine what types of fig

208 p < 0.001), with a higher rate of peripheral vascular disease, known coronary artery disease, chronic

209 One prominent hypothesis suggests that vascular disease leaf scorch is caused by fungal pathoge

210 he ability to monitor progression of retinal vascular diseases like diabetic retinopathy in small ani

211 eractions between indoor incense burning and vascular disease markers upon cognitive functions.

212 y of APOE-e4 status, suggesting that risk of vascular disease may not contribute a "second hit" to AD

213 The etiology of some oxidative vascular diseases may very well be explained by the dysf

214 cular framework to understand organ-specific vascular disease mechanisms and therapeutic targeting of

215 In the search for markers and modulators of vascular disease, microRNAs (miRNAs) have emerged as pot

216 episodes (VOEs) of sickle cell disease as a vascular disease model, we show that stress promotes VOE

217 othesize that many GWAS loci associated with vascular diseases modulate endothelial functions.

218 ere are many different causes of cardiac and vascular disease, most causes share an important patholo

219 shock, renal disease, history of peripheral vascular disease, multivessel disease, widowhood, and la

220 Patient age, sex, race, diabetes, vascular disease, obesity, and AVF location were not ass

221 However, as the treatment of vascular diseases often requires a high drug concentrati

222 now More Than We Can Tell About Diabetes and Vascular Disease," on Sunday, 12 June 2016.Diabetes is a

223 nd III obesity were 2.2 (95% CI 1.9-2.6) for vascular disease only (coronary heart disease or stroke)

224 l fibrillation trial (versus atherosclerotic vascular disease or diabetes mellitus/pre-diabetes melli

225 hypertension, and the majority had no known vascular disease or heart failure.

226 )] and greater odds of large-vessel cerebral vascular disease or history of cardiovascular disease bu

227 CL: 1.08 to 1.34), and underlying peripheral vascular disease (OR: 4.86; 95% CL: 1.66 to 14.22).

228 y event, a cerebrovascular event, peripheral vascular disease, or heart failure), death, myocardial i

229 ic obstructive pulmonary disease, peripheral vascular disease, or renal disease.

230 (with inflammatory bowel disease, mesenteric vascular diseases, or other conditions).

231 ciated with an increased likelihood of major vascular disease (P = .9038).

232 dal vasculopathy (PCV) is a common choroidal vascular disease particularly in Asians.

233 ng continues to advance our understanding of vascular disease pathophysiology.

234 om the ADVANCE study (Action in Diabetes and Vascular Disease: Peterax and Diamicron MR Controlled Ev

235 ing Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics) program undergo an extensive

236 The underlying pulmonary hypertensive vascular disease (PHVD) is characterized by inflammation

237 , high cholesterol, hypertension, peripheral vascular disease, physical activity, smoking, and histor

238 Among 5529 individuals without vascular disease, pravastatin reduced the risk of corona

239 , history of diabetes mellitus or peripheral vascular disease, primary renal disease classification,

240 utative ubiquitin ligase mutated in Moyamoya vascular disease, protected cells from lipotoxicity.

241 Pulmonary vascular disease, pulmonary endothelial dysfunction, liv

242 Early pulmonary vascular disease (PVD) after preterm birth is associated

243 medical practitioners in treating Peripheral Vascular Disease (PVD) and Coronary Artery Disease (CAD)

244 The association between peripheral vascular disease (PVD) and survival among kidney transpl

245 adjusted according to history of peripheral vascular disease (PVD).

246 ave traditionally been viewed as a marker of vascular disease, recent pathology studies have found an

247 revealed significant comorbidity of eye and vascular diseases (relative risks 2-15); this comorbidit

248 signatures identify cell subpopulations with vascular disease-relevant functions.

249 Patients with atherosclerotic vascular disease remain at high risk for cardiovascular

250 osis (SSc) is a multisystem inflammatory and vascular disease resulting in extensive tissue fibrosis.

251 atic diseases (RR 1.5 [1.3-1.7]), peripheral vascular disease (RR 1.4 [1.1-1.7]), surgery for trauma

252 Small cerebral vascular disease (SCeVD) demonstrated by white matter hy

253 h as atherosclerosis, restenosis, peripheral vascular disease, sepsis, and acute respiratory distress

254 tion characterized by severe and early-onset vascular disease similar to FMD and variable penetrance

255 terstitial fibrosis and tubular atrophy, and vascular disease; specimens with a score of 0 or 1 (scal

256 des insights into the influence of pulmonary vascular disease, spontaneous respiration and dynamic st

257 ata collection for this analysis on systemic vascular diseases started on December 2, 2010, and ended

258 osis, with implications for a broad range of vascular disease states.

259 ravastatin in Elderly Individuals at Risk of Vascular Disease Study), then pooled by using random eff

260 MP and TGFbeta signaling are instrumental in vascular disease such as vascular calcification and athe

261 endothelial function and is dysregulated in vascular diseases such as atherosclerosis and pulmonary

262 e impairments of neurovascular coupling from vascular diseases such as diabetic mellitus.

263 gene have been associated with the onset of vascular diseases such the Ehlers-Danlos syndrome.

264 herosclerosis from large-artery inflammatory vascular disease, such as Takayasu arteritis, chemothera

265 idual's risk of developing various pulmonary vascular diseases, such as pulmonary hypertension.

266 and effective therapy to treat inflammatory vascular diseases, such as sepsis and acute respiratory

267 of miR-145 and circ_Lrp6 in murine and human vascular diseases suggests that the ratio of circ_Lrp6 b

268 6 years younger, with more severe pulmonary vascular disease than patients with Ipc-PH, despite simi

269 ich leads to persistent airway and pulmonary vascular disease that can affect adult lung function.

270 e used to develop a global score of systemic vascular disease that included aorta and coronary artery

271 m of cell death found at the core of chronic vascular disease that is instigated by leukocytes and ca

272 represents an intrinsic mechanism for human vascular disease that manifests clinical complications i

273 cic aortic dissection (TAD) is an aggressive vascular disease that requires early diagnosis and effec

274 c aneurysm and dissections (AADs) are common vascular diseases that carry a high mortality rate.

275 SSPiM is a novel imaging feature of retinal vascular diseases that was not appreciated prior to the

276 In 2 young children with retinal vascular disease, the MIOCTA images showed more detailed

277 In the case of ischemic stroke and other vascular diseases, the endothelium overexpresses specifi

278 cardiometabolic risk factors and subtypes of vascular disease, thereby suggesting differing roles in

279 However, excessive levels of ROS promote vascular disease through direct and irreversible oxidati

280 enhanced genetic susceptibility to pulmonary vascular disease through epigenetic modifications or ger

281 rain connectivity; and (3) it interacts with vascular disease to predispose poor cognitive performanc

282 rposing to numerous indications ranging from vascular diseases to metastatic cancer.

283 rtly after diabetes onset that progresses to vascular disease underlying the majority of diabetes-ass

284 hemic cerebrovascular disease and peripheral vascular disease), we found independent associations of

285 pathogenic basis of KIF11-associated retinal vascular disease, we generated a Kif11 conditional knock

286 erized tomography among PLWHIV without known vascular disease were described.

287 lyses, 5529 participants without evidence of vascular disease were included, stratified by LDL-C leve

288 cteristics, although diabetes and peripheral vascular disease were more common in the usual-care grou

289 COMPASS patients with vascular disease were risk stratified using 2 methods: t

290 to endothelial cell dysfunction in diabetic vascular disease where tRES-HESP may provide effective t

291 EX) syndrome may be associated with systemic vascular diseases, which might suggest a broader health

292 nd the management of patients with pulmonary vascular disease who have right-sided heart failure.

293 involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastat

294 Among patients with atherosclerotic vascular disease who were receiving intensive statin the

295 Individuals with stable atherosclerotic vascular disease, who were treated with intensive atorva

296 aortic aneurysm (AAA) is a life-threatening vascular disease with an up to 80% mortality in case of

297 nal aortic aneurysm (AAA) is an inflammatory vascular disease with high mortality and limited treatme

298 urysm (AAA) remains the second most frequent vascular disease with high mortality but has no approved

299 Esca in grapevine (Vitis vinifera) is a vascular disease with huge negative effects on grape yie

300 ked to pulmonary hypertension (PH), a deadly vascular disease with poorly defined molecular origins.